Lilly plans new trial of Alzheimer's hope solanezumab

13 December 2012

US drug major Eli Lilly (NYSE: LLY) is planning to carry out an additional Phase III trial of its Alzheimer's disease candidate solanezumab, even though its earlier studies with the drug did not meet their primary endpoints.

The drugmaker said it has held discussions with regulatory authorities in the USA, Europe and Canada and will start another study of solanezumab in patients with mild Alzheimer's deal no later than the third quarter of 2013.

There had been suggestions that Lilly may try to press ahead with a filing for the anti-amyloid drug in the USA based on the results of the EXPEDITION and EXPEDITION 2, which did show a statistically significant 34% slowing of cognitive decline on a subset of patients across the two studies (The Pharma Letter October 9).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK